SCHEMBL21022150

SCHEMBL21022150

O=C(Nc1ccc(F)cc1)c1ccccc1C(F)(F)F

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.66
KCNK3 O14649 3/20 0.61
KCNK9 Q9NPC2 3/20 0.61
PTGS1 P23219 2/20 0.61
PTPRC P08575 1/20 0.60
GAA P10253 1/20 0.60
KDM4E B2RXH2 1/20 0.59
MAPT P10636 1/20 0.59
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
RXFP1 Q9HBX9 1/20 0.56
F2R P25116 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
PTGES O14684 2/20 0.52
PDE3B Q13370 1/20 0.51
PDE3A Q14432 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5332281 0.88 KCNK3 (0.75) LMNAKCNK3KCNK9PTGS1PTPRC
SCHEMBL2638776 0.87 PTGS1 (0.70) LMNAKCNK3KCNK9PTGS1PTPRC
SCHEMBL8363754 0.86 KCNK3 (0.64) LMNAKCNK3KCNK9PTGS1PTPRC
SCHEMBL3335567 0.86 KCNK3 (0.59) LMNAKCNK3KCNK9PTGS1PTPRC
SCHEMBL678924 0.86 PTGS1 (0.72) LMNAKCNK3KCNK9PTGS1PTPRC
SCHEMBL96040 0.86 KCNK3 (0.59) LMNAKCNK3KCNK9PTGS1PTPRC
SCHEMBL20601679 0.84 KCNK3 (0.66) LMNAKCNK3KCNK9PTGS1PTPRC
SCHEMBL21652266 0.83 PTGES (0.62) LMNAKCNK3KCNK9PTGS1PTPRC
SCHEMBL30791183 0.83 LMNA (0.69) LMNAKCNK3KCNK9PTGS1PTPRC
SCHEMBL6815792 0.83 MEN1 (0.54) LMNAKCNK3KCNK9PTGS1PTPRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112384505-B Therapeutic heterocyclic compounds 吉利德科学公司 2025-05-27 CN disclosed
CN-112384283-B Therapeutic heterocyclic compounds 吉利德科学公司 2023-08-15 CN disclosed
US-20200031801-A1 THERAPEUTIC HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. 2020-01-30 US disclosed
EP-3283459-B1 MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO DOW AGROSCIENCES LLC (US) 2019-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200031801-A1 THERAPEUTIC HETEROCYCLIC COMPOUNDS SDHA, SLC10A1, CYP11B2 LMNA 1413/4885KCNK3 3280/4885KCNK9 2746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.